Renal atrophy following gated delivery of stereotactic ablative radiotherapy to adrenal metastases | Zendy

John R. van Sörnsen de Koste | Zendy; Claire C. van Vliet | Zendy; Famke L. Schneiders | Zendy; A. Bruynzeel | Zendy; Ben J. Slotman | Zendy; M. Palacios | Zendy; Suresh Senan | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Renal atrophy following gated delivery of stereotactic ablative radiotherapy to adrenal metastases

Author(s) -

John R. van Sörnsen de Koste,

Claire C. van Vliet,

Famke L. Schneiders,

A. Bruynzeel,

Ben J. Slotman,

M. Palacios,

Suresh Senan

Publication year - 2021

Publication title -

physics and imaging in radiation oncology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.777

H-Index - 12

ISSN - 2405-6316

DOI - 10.1016/j.phro.2021.09.001

Subject(s) - sabr volatility model , medicine , ablative case , radiation therapy , kidney , renal function , urology , radiology , nuclear medicine , volatility (finance) , stochastic volatility , financial economics , economics

Stereotactic ablative radiotherapy (SABR) planning for adrenal metastases aims to minimize doses to the adjacent kidney. Renal dose constraints for SABR delivery are not well defined. In 20 patients who underwent MR-guided breath-hold SABR in five daily fractions of 8-10 Gy, ipsilateral renal volumes receiving ≥20 Gy best correlated with loss of renal volumes, with median renal volume reduction being 6% (range: 3%-11%, 10th-90th percentiles). Organ function did not deteriorate in 18 patients, who had post treatment renal function tests available. This suggests that the ipsilateral renal volume receiving 20 Gy can be used as partial organ dose constraint for SABR to targets in the upper abdomen.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research